புதுமையானது மருந்து முயற்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
New project aims to identify quantitative biological features common across diseases
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
What Impact can Handling of Protein Drugs have on Efficacy?
labmate-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labmate-online.com Daily Mail and Mail on Sunday newspapers.
Credit: Laura Alvarez, CeMM
Numerous disease development processes are linked to epigenetic modulation. One protein involved in the process of modulation and identified as an important cancer marker is BRD4. A recent study by the research group of Giulio Superti-Furga, Principal Investigator and Scientific Director at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, now shows that the supply of purines as well as the purine synthesis of a cell can influence BRD4 activity and thus play a role in the carcinogenesis process. The findings were published in
Nature Metabolism.
Chromatin is a central component of the cell nucleus. It refers to the complex of the approximately two-meter-long human DNA with proteins that organize it so that - depending on the cell type - certain genes are activated or deactivated. In order to be able to adapt to diverse situations and influences, cells read the information relevant to them from the DNA. If this process
AU, Nigeria back WHO on use of AstraZeneca COVID-19 vaccine
dailytrust.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailytrust.com Daily Mail and Mail on Sunday newspapers.
Dyadic International, Inc.: Dyadic to Present at ZAPI Stakeholders Virtual Meeting
JUPITER, FL / ACCESSWIRE / February 3, 2021 / Dyadic International, Inc. ( Dyadic ) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced that Ronen Tchelet, PhD, Dyadic s Chief Scientific Officer, will make a presentation during the European Union Innovative Medicines Initiative (IMI) Zoonotic Anticipation Preparedness Initiative - ZAPI Stakeholders Virtual Web Meeting to be held on February 4th and 5th, 2020. Dyadic s C1 gene expression platform has played an important role in the success of the ZAPI project , said Mark Emalfarb, Dyadic s CEO. Mr Emalfarb continued Our participation in the ZAPI project has led to several fully funded animal health